These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25444605)

  • 1. A computational method for computing an Alzheimer's disease progression score; experiments and validation with the ADNI data set.
    Jedynak BM; Liu B; Lang A; Gel Y; Prince JL;
    Neurobiol Aging; 2015 Jan; 36 Suppl 1():S178-84. PubMed ID: 25444605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
    Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
    J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort.
    Jedynak BM; Lang A; Liu B; Katz E; Zhang Y; Wyman BT; Raunig D; Jedynak CP; Caffo B; Prince JL;
    Neuroimage; 2012 Nov; 63(3):1478-86. PubMed ID: 22885136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease.
    Archetti D; Ingala S; Venkatraghavan V; Wottschel V; Young AL; Bellio M; Bron EE; Klein S; Barkhof F; Alexander DC; Oxtoby NP; Frisoni GB; Redolfi A; ;
    Neuroimage Clin; 2019; 24():101954. PubMed ID: 31362149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DeepAtrophy: Teaching a neural network to detect progressive changes in longitudinal MRI of the hippocampal region in Alzheimer's disease.
    Dong M; Xie L; Das SR; Wang J; Wisse LEM; deFlores R; Wolk DA; Yushkevich PA;
    Neuroimage; 2021 Nov; 243():118514. PubMed ID: 34450261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing the effect of APOE on Alzheimer's disease progression using an event-based model for stratified populations.
    Venkatraghavan V; Klein S; Fani L; Ham LS; Vrooman H; Ikram MK; Niessen WJ; Bron EE;
    Neuroimage; 2021 Feb; 227():117646. PubMed ID: 33338617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.
    Grill JD; Di L; Lu PH; Lee C; Ringman J; Apostolova LG; Chow N; Kohannim O; Cummings JL; Thompson PM; Elashoff D;
    Neurobiol Aging; 2013 Jan; 34(1):62-72. PubMed ID: 22503160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease.
    Morrison C; Dadar M; Shafiee N; Collins DL;
    Hum Brain Mapp; 2023 Jun; 44(8):3147-3157. PubMed ID: 36939138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing progression biomarkers in clinical trials of early Alzheimer's disease.
    Cullen NC; Zetterberg H; Insel PS; Olsson B; Andreasson U; ; Blennow K; Hansson O; Mattsson-Carlgren N
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1661-1673. PubMed ID: 32779869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Crane PK; Carle A; Gibbons LE; Insel P; Mackin RS; Gross A; Jones RN; Mukherjee S; Curtis SM; Harvey D; Weiner M; Mungas D;
    Brain Imaging Behav; 2012 Dec; 6(4):502-16. PubMed ID: 22782295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
    Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
    Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
    Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
    Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative.
    Braskie MN; Thompson PM
    Biol Psychiatry; 2014 Apr; 75(7):527-33. PubMed ID: 24367935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of an interpretable deep learning framework for Alzheimer's disease classification.
    Qiu S; Joshi PS; Miller MI; Xue C; Zhou X; Karjadi C; Chang GH; Joshi AS; Dwyer B; Zhu S; Kaku M; Zhou Y; Alderazi YJ; Swaminathan A; Kedar S; Saint-Hilaire MH; Auerbach SH; Yuan J; Sartor EA; Au R; Kolachalama VB
    Brain; 2020 Jun; 143(6):1920-1933. PubMed ID: 32357201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.